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Potential Risk for Dengue Hemorrhagic Fever:The Isolation
of Serotype Dengue-3 in Mexico
The Americas have a long history of dengue
epidemics, which present public health problems
becauseofthepotentialemergenceofdenguehem-
orrhagic fever (DHF) (1). Efforts to control Aedes
aegypti—the only demonstrated vector of dengue
virus in the Americas—were effectively deployed
in the 1950s and 1960s when the Pan American
Health Organization launched a continental
eradication campaign against yellow fever (2).
Aedes aegypti was eliminated in Mexico in 1963
(3). However, subsequent social and economic
changes in the Americas have permitted the rapid
reinfestation of the vector throughout the region.
In Mexico,population movement from rural areas
to urban centers—brought about by intensive in-
dustrialization—were not matched with adequate
housing and sufficient water, sewage, and waste
management systems. The introduction and pro-
liferation of nonrecyclable products provided nu-
merous and effective breeding sites for urban
mosquitoes. For example, from 1960 to 1990, the
annual production of bottles in Mexico increased
from 500,000 to 3.5 million, and the annual pro-
duction of tires increased from 2 to 17 million (4).
Tourism and travel, promoted as essential to the
national economy, have also become important
mechanisms for transporting dengue viruses. Ad-
ditionally, surveillance, prevention, and control
programs lack the infrastructure and human re-
sources needed to tackle this neglected health
problem(1,4).Millionsofpeoplelivinginthetropi-
cal and subtropical areas of the region face the
r e e m e r g e n c eo fd e n g u ea n dD H F( 2 ) .
In Mexico from 1984 to 1993, DHF cases were
sporadically reported; only 26 cases were identi-
fied,followed by 30 cases in 1994 (4).During 1995,
however,the General Directorate of Epidemiology
of the Ministry of Health in Mexico confirmed 358
DHF cases in 18 states with a case-fatality rate of
7.8% (unpublished data). The widespread distri-
bution of DHF cases and of the vector and the
circulation of different serotypes demonstrate the
risk of serious illness throughout the country.
Dengue fever in endemic-disease areas is often
not diagnosed properly because of its nonspecific
clinical manifestations. Furthermore, only pa-
tients with symptoms are treated, and patients
rarely demand medical care; thus, the proportion
of infected persons in the population is usually
underestimated (5).On the other hand,DHF is an
acute, life-threatening disease that requires spe-
cializedtreatmentinamedicalsetting.Identifying
dengue serotypes in the continent is one of the
most serious problems faced by every surveillance
system in the region. The serotype, strain, and
sequence of infections by different serotypes are
among the most meaningful risk factors for DHF;
thus, creating a strong dengue virus surveillance
system inevery countryintheAmericas shouldbe
a high priority (6, 7).
Serologic evidence of dengue in the Americas
can be traced back to 1941 in Panama (8). DEN-2
was isolated in Trinidad in 1953 (9). DEN-3 was
isolated in the Caribbean and Venezuela in 1963
(2,10), DEN-1 was introduced to the Americas in
1977,and DEN-4 affected the region 4 years later.
In 1981, Cuba had a major DHF epidemic caused
byanewstrainofDEN-2(11).DEN-3wasdetected
in Nicaragua and Panama in 1994 and in Costa
Rica in 1995 (12), after a long absence from the
region; a strain similar to one in Sri Lanka and
India in the 1980s caused the DHF epidemics in
those countries (12). The identification of DEN-3
in the region increases the probability of DHF
casesassociatedwithanewlycirculatingserotype.
In Mexico, this particular situation may have im-
portant epidemiologic consequences for several
reasons: 1) DEN-3 has not been identified in the
country, and the population is totally susceptible
to infection by this serotype;2)infectionby DEN-3
would most likely be of the secondary type;
3) population movements through Mexico and to-
wardsothercountries,mightdisseminatethisnew
serotype to areas where susceptible persons will
be exposed to a new serotype; and 4) intensive
transmission of dengue would naturally increase
the risk for DHF epidemics.
SurveillanceofdenguevirusinMexicobeganin
1982 when seven isolates of DEN-1 and DEN-2
were identified from outbreaks reported in the
south and southeastern regions of the country.
From 1982 to 1995, the National Institute of
Epidemiological Diagnosis and Reference (INDRE)
identified 681 dengue virus isolates.Serotypes were
identified by indirect immunofluorescence with spe-
cificmonoclonalantibodiesdonatedbytheDivision
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DEN-1 was the serotype most frequently iso-
lated from 1982 to 1995 (47% of all isolates), fol-
lowed by DEN-4 (30%) and DEN-2 (21%) (Table).
In 1995,DEN-3 was identified in 19 patients with
classicdenguefeverwithnohemorrhagicmanifes-
tations (Table). Beginning in 1995, active surveil-
lance for dengue cases was begun in areas where
transmission had been documented. Sentinel sur-
veillance centers were implemented to obtain se-
rum samples from febrile patients with a clinical
p i c t u r es u g g e s t i v eo fd e n g u ea n dt oi s o l a t ea n d
identify the serotype involved. From August to
December 1995, 245 isolates of dengue virus were
obtained, which represented 36% of isolates ob-
tained during the 14-year period. The prevalence
of serotypes isolated in 1995 differed from those
isolated from 1982 to 1994;DEN-1 was isolated in
only 16% of the samples processed, whereas 40%
wereDEN-2,8%wereDEN-3,and36%wereDEN-
4 (Figure 1). It is unclear whether the change in
distribution of serotypes is due to more intensive
surveillance in certain areas or in a manifestation
of herd immunity to serotype 1. This is the first
report of DEN-3 in Mexico and reflects the
strengthening of the surveillance at INDRE for
dengue viruses in areas at risk.
The geographic and temporal distribution of
DEN-3isolatedin1995inMexico(Figure2)shows
a pattern similar to the one followed by the first
dengue epidemics in the early 1980s (2) and may
be related to population movements towards the
northern border. The role of DEN-3 in increasing
DHF cases is still to be determined; to date none
of the DHF cases in which dengue virus was iso-
latedhavebeenassociatedwiththisserotype.Five
cases were associated with DEN-1 and 20 cases
with DEN-2.Nevertheless,the infection of DEN-3
in persons sensitized by previous infections with
other serotypes and the widespread susceptibility
ofthe Mexicanpopulationtothisserotypemustbe
considered a potential risk factor for future out-
breaks.
The cost of each DHF case has not been fully
determined, but the resources needed to face a
DHF epidemic are certainly not available in
countries where the health sector has financial
constraints due to unstable economic conditions.
The development of dengue vaccines is encourag-
ing, but the widespread dispersion of mosquito
breeding sites exceeds the capabilities of vector
control programs. Moreover, the potential role of
Table.Number of isolates of dengue virus serotypes in
Mexico*
Year DEN-1 DEN-2 DEN-3 DEN-4 Total
1982 2 5 0 0 7
1983 5 6 0 2 13
1984 89 2 0 38 129
1985 30 8 0 9 47
1986 65 0 0 24 89
1987 13 0 0 0 13
1988 28 0 0 0 28
1989 21 0 0 0 21
1990 6 0 0 0 6
1991 4 0 0 20 24
1992 1 5 0 19 25
1993 0 10 0 0 10
1994 15 9 0 0 24
1995 40 98 19 88 245
Total 319 143 19 200 681
*SerumsamplesfromsuspectcaseswereaddedtoC6-36cellsgrowninD-MEM
with5% fetalcalfserum for7daysat28°Candincubatedfor1hour.Cellswere
washed and further incubated in D-MEM with 0.4% bovine albumin for identifi-
cation of cytopathic effect.
Figure 2. Geographic and temporal distribution of
DEN-3 serotype in Mexico.
Figure 1. Frequency of dengue serotypes isolated in
1982 to 1994 and in 1995.
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virus in Mexico must be evaluated because DHF
cases have appeared in areas where A. albopictus
has been identified (14). The role of this vector in
denguetransmissioncouldincreaseshoulditsgeo-
graphic distribution expand and its susceptibility
to infection increase (15).
The challenge faced by national health services
is to improve the early detection of dengue trans-
mission, prevent DHF, and decrease the case-
fatality rate in DHF patients. This strategy must
be supported by a strong surveillance network for
viral diseases,whichisnowbeingimplementedon
a regional basis according to the risk of dengue
transmission in the country. The detailed knowl-
edge of the serotypes involved in future epidemics
willprovideusefulinformationthatwilldefinethe
role of each serotype in the genesis of DHF cases
andtargetcontrolmeasures.Thethreatofa major
epidemic requires a control strategy that will pre-
vent the emergence of this public health problem.
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